Kintor's Androgen Agonist Reduces COVID-19 Mortality in Hospitals by 92%

Suzhou Kintor Pharma reported that proxalutamide, its androgen receptor agonist, reduced mortality risk in newly hospitalized COVID-19 patients by 92% (3.7% vs 47.6%). It also shortened median hospital length stay by 9 days (median of 5 days vs 14 days). The results came from a investigator-led trial in Brazil that enrolled 588 patients and compared proxalutamide plus standard care to standard care alone. Kintor is developing proxalutamide for COVID-19, prostate cancer and breast cancer. More details.... Stock Symbol: (HK: 9939) Share this with colleagues: // //